热门资讯> 正文
Xoma Royalty以3000万美元从BioInvent International购买mezagitamab版税权
2025-05-27 20:47
- 标记临床研究(XOMA) 0
- XOMA Corp 8.375% PRF PERPETUAL USD 25 - Ser B 1/1000th(XOMAO) 0
- Brandes International ETF(BINV) 0
- XOMA Royalty (NASDAQ:XOMA) and BioInvent International (BINV) said on Tuesday that XOMA Royalty has purchased the future mezagitamab royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $30 million.
- The future royalty and milestone economics interest in mezagitamab originated from a 2003 cross-licensing agreement covering XOMA Royalty’s legacy bacterial protein expression technology and BioInvent’s n-CoDeR antibody library.
- Under the terms of XOMA Royalty’s purchase of BioInvent’s economic interest in mezagitamab, XOMA Royalty paid USD $20 million to BioInvent at closing and will pay an additional USD $10 million upon mezagitamab achieving a specific pre-defined regulatory milestone.
- With its existing entitlement, plus the newly acquired economics from BioInvent, XOMA Royalty will be entitled to milestones of up to USD $16.25 million from Takeda and mid-single digit royalties on future mezagitamab commercial sales.
More on XOMA
- XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist
- Seeking Alpha’s Quant Rating on XOMA
- Historical earnings data for XOMA
- Financial information for XOMA
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
